A phase 2 study investigated the use of cord blood–derived natural killer cells plus elotuzumab, lenalidomide, and melphalan with autologous stem cell transplant for patients with high-risk multiple myeloma.
Samer A. Srour, MB, ChB, MS
Advertisement
Articles by Samer A. Srour, MB, ChB, MS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Pembrolizumab/Belzutifan Improves DFS in ccRCC Following Nephrectomy
2
What is the Impact of the SHARON Trial on Pancreatic Cancer Research?
3
Neoadjuvant Pembrolizumab/Radiotherapy Earns EU Approval in HNSCC Group
4
ZEN-3694 Earns FDA Orphan Drug Designation in NUT Carcinoma
5
